Program
| PUBLISHED APRIL 27 | Access sessions here. |
| Introduction and Welcome Notes | Howard Fillit, MD—Alzheimer’s Drug Discovery Foundation |
| SESSION I. DRUG DISCOVERY 2.0 | CHAIR: Walter Kostich, PhD—National Multiple Sclerosis Society |
| Omics to Identify Novel Target for Neurodegenerative Diseases | Philip De Jager, MD, PhD—Columbia University |
| Pre-clinical Science, Clinical Development and Pathway to Marketing Approval of a Living Cell Pharmaceutical for AD – the Mesenchymal Stem/Stromal Cell Paradigm | Jacques Galipeau, MD—University of Wisconsin, Madison |
| Shift in Medicinal Chemistry: from Organic Chemistry to Synthetic Biology | Edmund Graziani, PhD—Apertor Labs |
| SESSION II. DRUG DISCOVERY: FROM TEST TUBE TO ANIMAL STUDIES | CHAIR: Nadine Tatton, PhD—The Association for Frontotemporal Degeneration (AFTD) |
| Compound Optimization after Target Identification: From HTS to Lead | Kurt Brunden, PhD—University of Pennsylvania |
| What Can We Still Learn from Studies in Animal Models of Neurodegenerative Disease? | Joseph Araujo—InterVivo Solutions |
| Translational PK/PD in Neurodegeneration | Natasha Penner, PhD—Biogen |
| PUBLISHED May 4 | Access this here. |
| SESSION III. FROM ANIMAL STUDIES TO HUMAN CLINICAL TRIALS | CHAIR: Lilliana Menalled, PhD—The Michael J. Fox Foundation |
| Requirements for an IND/Toxicology | Kenneth Olivier, PhD—Olivier KOnsulting |
| What are Biomarkers and Why Should I Develop Them? | John Gerdes, PhD—Rio Pharma |
| How to Run a Clinical Trial? | Anita DiFrancesco—Samumed |
| KEYNOTE: The Clinical Potential of Senolytic Drugs | James Kirkland, MD, PhD—Mayo Clinic |
| SHORT TALKS Brief presentations of scholarship winners and accepted abstract submitters | |
| PUBLISHED May 11 | Access this here. |
| SESSION IV. I WISH I KNEW... (PRECLINICAL) | CHAIR: Leticia Toledo-Sherman, PhD—Rainwater Charitable Foundation |
| Case Study: Challenges in Biomarker Development for Huntington's Disease | Douglas Macdonald, PhD—CHDI Foundation |
| Case Study: Alzheimer’s Disease Drug Discovery: NMEs vs. NCEs, Pros and Cons of Each | Allen Reitz, PhD—ALS Biopharma |
| Case Study: Challenges in Drug Development for Neurodegenerative Disease | Leticia Toledo-Sherman, PhD—Rainwater Charitable Foundation |
| Case Study: Development of Novel Stress Kinase Inhibitor | D. Martin Watterson, PhD—Northwestern University |
| SESSION V. CLINICAL CASE STUDIES AND COMMERCIALIZATION STRATEGIES | CHAIR: Kuldip Dave, PhD—The ALS Association |
| Case Study: Challenges Associated with Biomarker Development in Neurodegenerative Conditions – “A Commercial Perspective” | Iswariya (Ishu) Venkataraman, PhD—Euroimmun |
| Case Study: SEMA4D Modulates Blood-Brain Barrier, Microglia, and Inhibits Remyelination in Neurodegenerative Disease | Maurice Zauderer, PhD—Vaccinex |
| The Handling of Drug Discovery IP and Paths to Commercialization | Maria Emanuel, PhD—University of New Hampshire |
| Developing your Team and Your Funding Strategy | Edward Spack, PhD—Vector BioSolutions/Therini |
| SHORT TALKS Brief presentations of scholarship winners and accepted abstract submitters | |
Funding Opportunities at NIH
Funding Opportunities in Neurodegenerative Diseases Panel
SCIENTIFIC ADVISORY COMMITTEE
Kurt Brunden, PhD—University of Pennsylvania
Kuldip Dave, PhD—ALS Association
Howard Fillit, MD—ADDF
Lauren Friedman, PhD—ADDF
Marcie Glicksman, PhD
Walter Kostich, PhD—National MS Society
Frank Longo, MD, PhD—Stanford University
Suzana Petanceska, PhD—NIH/NIA
Edward Spack, PhD—Vector BioSolutions/Therini
Alessio Travaglia, PhD—ADDF
D. Martin Watterson, PhD—Northwestern University